Positive News SentimentPositive NewsNASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News $24.53 -0.37 (-1.49%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$24.40▼$25.0450-Day Range$24.53▼$28.1752-Week Range$21.07▼$31.87Volume223,034 shsAverage Volume328,958 shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agios Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside46.8% Upside$36.00 Price TargetShort InterestBearish11.04% of Float Sold ShortDividend StrengthN/ASustainability-0.53Upright™ Environmental ScoreNews Sentiment1.61Based on 2 Articles This WeekInsider TradingSelling Shares$1.65 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.29) to ($4.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector513th out of 963 stocksPharmaceutical Preparations Industry237th out of 458 stocks 3.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Agios Pharmaceuticals has a forecasted upside of 46.8% from its current price of $24.53.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.04% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 1.01%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 76.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.53. Previous Next 3.1 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest3 people have searched for AGIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,645,858.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Agios Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.29) to ($4.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Agios Pharmaceuticals (NASDAQ:AGIO) StockAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesSeptember 14, 2023 | markets.businessinsider.comNektar Therapeutics (NKTR) Gets a Sell from Bank of America SecuritiesSeptember 9, 2023 | finanznachrichten.deRegeneron Pharmaceuticals, Inc.: Regeneron Announces Updates to Board of DirectorsSeptember 24, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 7, 2023 | finance.yahoo.comWhy Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?September 3, 2023 | markets.businessinsider.comJ.P. Morgan Reaffirms Their Hold Rating on Sana Biotechnology (SANA)August 30, 2023 | uk.finance.yahoo.comAgios Pharmaceuticals Inc (8AP.BE)August 29, 2023 | finance.yahoo.comAgios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023August 22, 2023 | benzinga.comAgios Pharmaceuticals Insider Trades Send a SignalSeptember 24, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 10, 2023 | benzinga.comPrincipal Accounting Officer At This Health Care Company Sells $74K of StockAugust 10, 2023 | finance.yahoo.comThe Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stakeAugust 8, 2023 | msn.comJP Morgan Maintains Agios Pharmaceuticals (AGIO) Neutral RecommendationAugust 4, 2023 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | finance.yahoo.comAgios (AGIO) Q2 Earnings Beat Estimates, Revenues In LineAugust 4, 2023 | finance.yahoo.comAgios Pharmaceuticals Second Quarter 2023 Earnings: Beats ExpectationsAugust 3, 2023 | finance.yahoo.comAgios Reports Business Highlights and Second Quarter 2023 Financial ResultsAugust 3, 2023 | markets.businessinsider.comHere's what Wall Street expects from Agios Pharmaceuticals's earningsJuly 28, 2023 | bizjournals.comThe highest-earning CEOs in Mass. are — surprise! — mostly menJuly 18, 2023 | finance.yahoo.comShould You Buy Agios Pharmaceuticals (AGIO) After Golden Cross?July 18, 2023 | fool.comBetter AI Biotech Stock: Schrödinger vs. Recursion PharmaceuticalsJuly 17, 2023 | finance.yahoo.comWall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a BetJuly 13, 2023 | finance.yahoo.comAgios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023June 28, 2023 | finance.yahoo.comAre Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?June 28, 2023 | finance.yahoo.comAre Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?June 28, 2023 | msn.comRBC Capital Maintains Agios Pharmaceuticals (AGIO) Outperform RecommendationJune 27, 2023 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To KnowJune 26, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Esperion (ESPR)See More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees389Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.00 High Stock Price Forecast$41.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+46.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-231,800,000.00 Net Margins-1,042.56% Pretax Margin-1,042.56% Return on Equity-20.24% Return on Assets-18.05% Debt Debt-to-Equity RatioN/A Current Ratio13.73 Quick Ratio13.45 Sales & Book Value Annual Sales$14.24 million Price / Sales96.02 Cash FlowN/A Price / Cash FlowN/A Book Value$20.03 per share Price / Book1.22Miscellaneous Outstanding Shares55,740,000Free Float53,376,000Market Cap$1.37 billion OptionableOptionable Beta0.95 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 54)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 48)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 45)Corp. Sec. & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 43)Ph.D., Chief Medical Officer and Head of R&D Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 74)Co-Founder & Member of Scientific Advisory Board Dr. Tak Wah Mak D.Sc. (Age 77)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 70)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 67)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 42)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 59)Chief Technical Operations Officer More ExecutivesKey CompetitorsRhythm PharmaceuticalsNASDAQ:RYTMCatalyst PharmaceuticalsNASDAQ:CPRXIronwood PharmaceuticalsNASDAQ:IRWDStructure TherapeuticsNASDAQ:GPCRTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 62,896 shares on 9/21/2023Ownership: 0.285%Virginia Retirement Systems ET ALBought 23,500 shares on 8/22/2023Ownership: 0.042%California State Teachers Retirement SystemBought 3,392 shares on 8/21/2023Ownership: 0.120%James William BurnsSold 6,395 sharesTotal: $168,060.60 ($26.28/share)Royal Bank of CanadaBought 4,946 shares on 8/15/2023Ownership: 0.089%View All Insider TransactionsView All Institutional Transactions AGIO Stock - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price forecast for 2023? 4 Wall Street analysts have issued 1 year price targets for Agios Pharmaceuticals' shares. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they anticipate the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 46.8% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2023? Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of the year. Since then, AGIO shares have decreased by 12.6% and is now trading at $24.53. View the best growth stocks for 2023 here. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AGIO earnings forecast. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.51) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.09. The biopharmaceutical company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.46 million. Agios Pharmaceuticals had a negative net margin of 1,042.56% and a negative trailing twelve-month return on equity of 20.24%. The business's quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.68) earnings per share. What ETFs hold Agios Pharmaceuticals' stock? ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Propel Opportunities ETF (SURI). What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.48%), Rock Springs Capital Management LP (4.82%), State Street Corp (4.63%), JPMorgan Chase & Co. (4.47%), Dimensional Fund Advisors LP (4.06%) and ArrowMark Colorado Holdings LLC (2.82%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $24.53. How much money does Agios Pharmaceuticals make? Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.37 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. How many employees does Agios Pharmaceuticals have? The company employs 389 workers across the globe. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com. This page (NASDAQ:AGIO) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.